Oric Pharmaceuticals, Inc.
A clinical-stage biopharmaceutical company developing medicines to fight drug-resistant cancers. Its two lead drugs are rinzimetostat, a pill for advanced prostate cancer, and enozertinib, a brain-penetrating treatment for certain lung cancers, with trials run alongside partners Johnson & Johnson and Bayer. The company was founded in 2014 by top cancer researchers, and its name is an acronym for "Overcoming Resistance In Cancer."
Granted 83.7K · Sold 283.4K
Granted 32.8K · Sold 6.7K
Granted 92.3K · Sold 73.7K
Granted 15.5K
Granted 29.3K · Sold 10.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Chacko JacobPRESIDENT AND CEO, Director · 6 transactions | -25.3% | 581.7K | 83.7K | — | 283.4K |
| Heyman Richard A.Director · 4 transactions | +11.4% | 254.9K | 32.8K | — | 6.7K |
| Piscitelli DominicChief Financial Officer · 6 transactions | +148.7% | 120.1K | 92.3K | — | 73.7K |
| Kunkel Lori AnneDirector · 2 transactions | +74.8% | 84.2K | 15.5K | — | — |
| Multani Pratik SChief Medical Officer · 2 transactions | +45.7% | 68.1K | 29.3K | — | 10.7K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -374.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.